MAS Medicines Development | |
Location | Basilea, North West Switzerland, Svizzera |
Categoria | Farmacologia Salute |
type | MAS |
The European Center of Pharmaceutical Medicine (ECPM) designs and organizes the Master of Advanced Studies in Medicines Development program, together with partnering universities throughout Europe and other health care partner organizations. The program emphasizes integrated drug development, which is science-based, innovative, efficient and of high quality - leading to better and safer medical products for patients. The ECPM belongs to the Department of Public Health of the Medical Faculty at the University of Basel and is accredited as "Centre of Excellence" by the Innovative Medicines Initiative (IMI) PharmaTrain Executive Board. All ECPM courses are accredited by IMI PharmaTrain and the International Federation of Associations of Pharmaceutical Physicians (IFAPP) by following the agreed syllabus and quality assurance, and are certified by the University of Basel within the Bologna Title System. The program is structured in modules, which allows it to be completed next to working full- or part-time. Students can enroll in both the ECPM course and the master program. In total, the Master of Advanced Studies requires a minimum of 60 ECTS. 30 ECTS will be accredited by successfully completing the two-year ECPM Diploma Course - a well-established postgraduate education and training program - and acquiring the Diploma of Advanced Studies (DAS). 20 ECTS will be accredited for completing the master modules selected from the Continuing Professional Development (CPD) short courses list. These can be chosen by preference either from the ECPM CPD short course program, from other course providers or partner universities which offer training relevant to drug development sciences and the IMI PharmaTrain syllabus. The remaining 10 ECTS will be accredited for writing and submitting a master thesis. The ECPM Advanced Studies degrees are targeted at representatives from the pharmaceutical industry, service industry, academic and government decision- and policy-makers who already have a good understanding of the basics of drug development and will benefit from a more in-depth, comprehensive and systematic immersion into modern medical product and device development, regulation and market introduction. In order to enroll in the ECPM Diploma Course and pursue the Master of Advanced Studies, applicants must have a higher university degree, such as a Master’s, MD, PharmD or PhD. Applicants should have a primary interest in medical product discovery, development, regulation and health care system. The program is particularly aimed at professionals who are involved in the drug development process and have already at least one to two years working experience. Applications sur dossier are possible on an individual basis. The ECPM teaching faculty consists of an international network of about +150 experts from academia, pharmaceutical industry, international organizations (e.g. WHO) and from regulatory authorities (e.g. EMA, FDA and local authorities). European Center of Pharmaceutical Medicine (ECPM)
Phone 0041 (0)61 207 19 50
Master Modules can be either chosen from the ECPM Continuing Professional Development (CPD) short courses program or from other Universities (20 ECTS; tuition fee depends on the courses chosen and the course provider) ECPM, European Center of Pharmaceutical Medicine, part of the Medical Faculty of the University of Basel together with selected universities and partners. After starting the ECPM Diploma Course you can register for the Master degree at any time and start collecting additional credit points. The maximum study time to qualify for the Master Degree is five years. Next registration deadline for the ECPM Diploma Course: June 30, 2021 Module 1 - September 6 - September 9, 2021
Host
European Center of Pharmaceutical Medicine (ECPM) Institute of Pharmaceutical Medicine University of Basel Klingelbergstrasse 61 CH-4056 Basel | |
In your contacts, please refer to myScience.ch and reference edu.myScience.ch/id2403 |
Related News
26.9.2024
I calcoli renali sono spesso espulsi in modo indolore
20.9.2024
Il promettente principio attivo contro il tumore cerebrale mortale è una vecchia conoscenza
2.9.2024
Nuovi principi attivi farmaceutici da miliardi di molecole appena combinate